9 results on '"Hideki Maki"'
Search Results
2. Genome analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki
- Author
-
Masataka Taguchi, Hiroyuki Mishima, Yusuke Shiozawa, Chisa Hayashida, Akira Kinoshita, Yasuhito Nannya, Hideki Makishima, Makiko Horai, Masatoshi Matsuo, Shinya Sato, Hidehiro Itonaga, Takeharu Kato, Hiroaki Taniguchi, Daisuke Imanishi, Yoshitaka Imaizumi, Tomoko Hata, Motoi Takenaka, Yukiyoshi Moriuchi, Yuichi Shiraishi, Satoru Miyano, Seishi Ogawa, Koh-ichiro Yoshiura, and Yasushi Miyazaki
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Ionizing radiation is a risk factor for myeloid neoplasms including myelodysplastic syndromes (MDS), and atomic bomb survivors have been shown to have a significantly higher risk of MDS. Our previous analyses demonstrated that MDS among these survivors had a significantly higher frequency of complex karyotypes and structural alterations of chromosomes 3, 8, and 11. However, there was no difference in the median survival time between MDS among survivors compared with those of de novo origin. This suggested that a different pathophysiology may underlie the causative genetic aberrations for those among survivors. In this study, we performed genome analyses of MDS among survivors and found that proximally exposed patients had significantly fewer mutations in genes such as TET2 along the DNA methylation pathways, and they had a significantly higher rate of 11q deletions. Among the genes located in the deleted portion of chromosome 11, alterations of ATM were significantly more frequent in proximally exposed group with mutations identified on the remaining allele in 2 out of 5 cases. TP53, which is frequently mutated in therapy-related myeloid neoplasms, was equally affected between proximally and distally exposed patients. These results suggested that the genetic aberration profiles in MDS among atomic bomb survivors differed from those in therapy-related and de novo origin. Considering the role of ATM in DNA damage response after radiation exposure, further studies are warranted to elucidate how 11q deletion and aberrations of ATM contribute to the pathogenesis of MDS after radiation exposure.
- Published
- 2020
- Full Text
- View/download PDF
3. Molecular features of early onset adult myelodysplastic syndrome
- Author
-
Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Tomas Radivoyevitch, Bhumika Patel, Swapna Thota, Michael J. Clemente, Yasunobu Nagata, Thomas LaFramboise, Hetty E. Carraway, Aziz Nazha, Mikkael A. Sekeres, Hideki Makishima, and Jaroslaw P. Maciejewski
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Myelodysplastic syndromes are typically diseases of older adults. Patients in whom the onset is early may have distinct molecular and clinical features or reflect a demographic continuum. The identification of differences between “early onset” patients and those diagnosed at a traditional age has the potential to advance understanding of the pathogenesis of myelodysplasia and may lead to formation of distinct morphological subcategories. We studied a cohort of 634 patients with various subcategories of myelodysplastic syndrome and secondary acute myeloid leukemia, stratifying them based on age at presentation and clinical parameters. We then characterized molecular abnormalities detected by next-generation deep sequencing of 60 genes that are commonly mutated in myeloid malignancies. The number of mutations increased linearly with age and on average, patients >50 years of age had more mutations. TET2, SRSF2, and DNMT3A were more commonly mutated in patients >50 years old compared to patients ≤50 years old. In general, patients >50 years of age also had more mutations in spliceosomal, epigenetic modifier, and RAS gene families. Although there are age-related differences in molecular features among patients with myelodysplasia, most notably in the incidence of SRSF2 mutations, our results suggest that patients ≤50 years old belong to a disease continuum with a distinct pattern of early onset ancestral events.
- Published
- 2017
- Full Text
- View/download PDF
4. Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes
- Author
-
Aziz Nazha, David Seastone, Tom Radivoyevitch, Bartlomiej Przychodzen, Hetty E. Carraway, Bhumika J. Patel, Jennifer Carew, Hideki Makishima, Mikkael A. Sekeres, and Jaroslaw P. Maciejewski
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2015
- Full Text
- View/download PDF
5. GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies
- Author
-
Xinan Wang, Hideki Muramatsu, Yusuke Okuno, Hirotoshi Sakaguchi, Kenichi Yoshida, Nozomu Kawashima, Yinyan Xu, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Shoji Saito, Yozo Nakazawa, Taro Masunari, Tadashi Hirose, Shaimaa Elmahdi, Atsushi Narita, Sayoko Doisaki, Olfat Ismael, Hideki Makishima, Asahito Hama, Satoru Miyano, Yoshiyuki Takahashi, Seishi Ogawa, and Seiji Kojima
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2015
- Full Text
- View/download PDF
6. BRCC3 mutations in myeloid neoplasms
- Author
-
Dayong Huang, Yasunobu Nagata, Vera Grossmann, Tomas Radivoyevitch, Yusuke Okuno, Genta Nagae, Naoko Hosono, Susanne Schnittger, Masashi Sanada, Bartlomiej Przychodzen, Ayana Kon, Chantana Polprasert, Wenyi Shen, Michael J. Clemente, James G. Phillips, Tamara Alpermann, Kenichi Yoshida, Niroshan Nadarajah, Mikkael A. Sekeres, Kevin Oakley, Nhu Nguyen, Yuichi Shiraishi, Yusuke Shiozawa, Kenichi Chiba, Hiroko Tanaka, H. Phillip Koeffler, Hans-Ulrich Klein, Martin Dugas, Hiroyuki Aburatani, Satoru Miyano, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach, Yang Du, Seishi Ogawa, and Hideki Makishima
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Next generation sequencing technologies have provided insights into the molecular heterogeneity of various myeloid neoplasms, revealing previously unknown somatic genetic events. In our cohort of 1444 cases analyzed by next generation sequencing, somatic mutations in the gene BRCA1-BRCA2-containing complex 3 (BRCC3) were identified in 28 cases (1.9%). BRCC3 is a member of the JAMM/MPN+ family of zinc metalloproteases capable of cleaving Lys-63 linked polyubiquitin chains, and is implicated in DNA repair. The mutations were located throughout its coding region. The average variant allelic frequency of BRCC3 mutations was 30.1%, and by a serial sample analysis at two different time points a BRCC3 mutation was already identified in the initial stage of a myelodysplastic syndrome. BRCC3 mutations commonly occurred in nonsense (n=12), frameshift (n=4), and splice site (n=5) configurations. Due to the marginal male dominance (odds ratio; 2.00, 0.84–4.73) of BRCC3 mutations, the majority of mutations (n=23; 82%) were hemizygous. Phenotypically, BRCC3 mutations were frequently observed in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms and associated with -Y abnormality (odds ratio; 3.70, 1.25–11.0). Clinically, BRCC3 mutations were also related to higher age (P=0.01), although prognosis was not affected. Knockdown of Brcc3 gene expression in murine bone marrow lineage negative, Sca1 positive, c-kit positive cells resulted in 2-fold more colony formation and modest differentiation defect. Thus, BRCC3 likely plays a role as tumor-associated gene in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
- Published
- 2015
- Full Text
- View/download PDF
7. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype
- Author
-
Valeria Visconte, Ali Tabarroki, Heesun J. Rogers, Edy Hasrouni, Fabiola Traina, Hideki Makishima, Betty K. Hamilton, Yang Liu, Christine O’Keefe, Alan Lichtin, Leonard Horwitz, Mikkael A. Sekeres, Fred H. Hsieh, and Ramon V. Tiu
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2013
- Full Text
- View/download PDF
8. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia
- Author
-
Sarah Abu Kar, Anna Jankowska, Hideki Makishima, Valeria Visconte, Andres Jerez, Yuka Sugimoto, Hideki Muramatsu, Fabiola Traina, Manuel Afable, Kathryn Guinta, Ramon V. Tiu, Bartlomiej Przychodzen, Hirotoshi Sakaguchi, Seiji Kojima, Mikkael A. Sekeres, Alan F. List, Michael A. McDevitt, and Jaroslaw P. Maciejewski
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Chronic myelomonocytic leukemia is a heterogeneous disease with multifactorial molecular pathogenesis. Various recurrent somatic mutations have been detected alone or in combination in chronic myelomonocytic leukemia. Recently, recurrent mutations in spliceosomal genes have been discovered. We investigated the contribution of U2AF1, SRSF2 and SF3B1 mutations in the pathogenesis of chronic myelomonocytic leukemia and closely related diseases. We genotyped a cohort of patients with chronic myelomonocytic leukemia, secondary acute myeloid leukemia derived from chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia for somatic mutations in U2AF1, SRSF2, SF3B1 and in the other 12 most frequently affected genes in these conditions. Chromosomal abnormalities were assessed by nucleotide polymorphism array-based karyotyping. The presence of molecular lesions was correlated with clinical endpoints. Mutations in SRSF2, U2AF1 and SF3B1 were found in 32%, 13% and 6% of cases of chronic myelomonocytic leukemia, secondary acute myeloid leukemia derived from chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia, respectively. Spliceosomal genes were affected in various combinations with other mutations, including TET2, ASXL1, CBL, EZH2, RAS, IDH1/2, DNMT3A, TP53, UTX and RUNX1. Worse overall survival was associated with mutations in U2AF1 (P=0.047) and DNMT3A (P=0.015). RAS mutations had an impact on overall survival in secondary acute myeloid leukemia (P=0.0456). By comparison, our screening of juvenile myelomonocytic leukemia cases showed mutations in ASXL1 (4%), CBL (10%), and RAS (6%) but not in IDH1/2, TET2, EZH2, DNMT3A or the three spliceosomal genes. SRSF2 and U2AF1 along with TET2 (48%) and ASXL1 (38%) are frequently affected by somatic mutations in chronic myelomonocytic leukemia, quite distinctly from the profile seen in juvenile myelomonocytic leukemia. Our data also suggest that spliceosomal mutations are of ancestral origin.
- Published
- 2013
- Full Text
- View/download PDF
9. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia
- Author
-
Manuel G. Afable, Mohammed Shaik, Yuka Sugimoto, Paul Elson, Michael Clemente, Hideki Makishima, Mikkael A. Sekeres, Alan Lichtin, Anjali Advani, Matt Kalaycio, Ramon V. Tiu, Christine L. O’Keefe, and Jaroslaw P. Maciejewski
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Background A combination of horse anti-thymocyte globulin and cyclosporine produces responses in 60–70% of patients with severe aplastic anemia. We performed a phase II study of rabbit anti-thymocyte globulin and cyclosporine as first-line therapy for severe aplastic anemia.Design and Methods Twenty patients with severe aplastic anemia treated with rabbit anti-thymocyte globulin were compared to 67 historical control cases with matched clinical characteristics treated with horse anti-thymocyte globulin.Results Response rates at 3, 6 and 12 months were similar for patients treated with rabbit anti-thymocyte globulin or horse anti-thymocyte globulin: 40% versus 55% (P=0.43), 45% versus 58% (P=0.44) and 50% versus 58% (P=0.61), respectively. No differences in early mortality rates or overall survival were observed. We then performed multivariable analyses of response at 6 months and overall survival and identified the presence of a paroxysmal nocturnal hemoglobinuria clone (P=0.01) and a pretreatment absolute reticulocyte count greater than 30×109/L (P=0.007) as independent predictors of response and younger age (P=0.003), higher pretreatment absolute neutrophil (P=0.02) and absolute lymphocyte counts (P=0.03) as independent predictors of overall survival. None of the immunogenetic polymorphisms studied was predictive of response to immunosupressive therapy.Conclusions Despite reports suggesting differences in biological activity of different anti-thymocyte globulin preparations, rabbit and horse anti-thymocyte globulin appear to have a similar efficacy for up-front treatment of severe aplastic anemia. Clinicaltrial.gov: NCT01231841)
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.